Industry / innovation partners

Brain Tumour Surgery Is Getting Smaller. Access Cannot Stay Elite.

Beyond GLP-1s: Lilly is spending billions on a more targeted future in neuroscience

Sanfilippo’s Approval Path Is Being Built Before Approval

AstraZeneca’s Wainua lowered a disease-causing protein but did not reduce heart complications in a major trial

FDA Is Asking the Right AI Question: Who Watches the Model After Approval?

Europe Made Genomics Mandatory.

Bladder Cancer Is Moving Into the Immunotherapy Maintenance Era

Duchenne’s Cell Therapy Gets More Time, Not Certainty

Radiopharmaceuticals Just Got a Necessary No
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
